Propranolol and Pregnancy
Propranolol is generally considered safe for use during pregnancy and is recommended as a first-line beta-blocker option, though it should ideally be avoided in the first trimester when possible, and requires monitoring for potential intrauterine growth restriction and neonatal complications. 1, 2
Safety Profile and Recommendations
Overall Safety Assessment
Propranolol carries an FDA Pregnancy Category C designation 3, meaning potential benefits may outweigh risks. Multiple major cardiology guidelines consistently classify propranolol among safe first-line agents for pregnancy due to its longer safety record 1. The 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline specifically states that propranolol (along with metoprolol, bisoprolol, labetalol, and pindolol) is "generally considered safe to use during pregnancy" 2.
The 2015 ESC guidelines categorize propranolol as FDA Category C, where "potential benefits outweigh the risk" 4, distinguishing it from Category D agents like atenolol and amiodarone that show "positive evidence of risk."
Timing Considerations
First Trimester: Antiarrhythmic drugs should be avoided when possible during the first trimester due to the greatest risk of congenital malformations 1. However, if clinically necessary, propranolol may be used as benefits can outweigh risks 5.
Second and Third Trimesters: Propranolol is considered appropriate for ongoing management during these periods 1.
Postpartum Period: Beta-blocker therapy should be continued throughout pregnancy and the postpartum period, particularly in conditions like congenital LQTS where there is substantial increase in cardiac event risk during the 40-week postpartum period 4. The 2023 Canadian guidelines emphasize that switching beta-blockers during pregnancy (e.g., to metoprolol) should be avoided, and nadolol or propranolol should be continued throughout pregnancy 6.
Clinical Indications
Propranolol receives Class IIa (Level C-LD) recommendations for:
- Ongoing management of highly symptomatic supraventricular tachycardia (SVT) in pregnant patients 1
- Acute treatment of SVT (Class IIa, Level C) 5
- Management of hypertrophic cardiomyopathy (HCM) during pregnancy 2, 7
- Portal hypertension management (compatible with all trimesters and breastfeeding) 8
- Long QT syndrome (LQTS) throughout pregnancy and postpartum 6
Dosing Strategy
Start with the lowest recommended dose initially, with adjustments based on clinical response 1. The guidelines emphasize beginning treatment "as late in pregnancy as possible" when feasible and using the "lowest effective dose" 4.
For pregnant women already on propranolol, continue the current medication rather than switching 6. Propranolol dosing may require adjustment to TID or QID due to accelerated drug metabolism during pregnancy 9.
Maternal and Fetal Risks
Fetal Risks Requiring Monitoring
Intrauterine Growth Restriction (IUGR): Beta-blocker therapy has been associated with IUGR 1. This effect is "especially pronounced with atenolol" rather than propranolol 1. The FDA label notes that "intrauterine growth retardation, small placentas, and congenital abnormalities have been reported in neonates whose mothers received propranolol during pregnancy" 3.
However, the risk appears lower with propranolol compared to atenolol. The 2024 HCM guidelines recommend "closer monitoring of fetal growth and surveillance for fetal bradycardia may be considered for pregnant women on beta-blockers" 2.
Neonatal Complications
Neonates whose mothers receive propranolol at parturition may exhibit:
- Bradycardia
- Hypoglycemia
- Respiratory depression
Adequate facilities for monitoring such infants at birth should be available 3. The 2023 Canadian guidelines note that "use of any beta-blocker at term might cause neonatal β-adrenoceptor blockade, so the neonate should be monitored for bradycardia, hypotension, and hypoglycemia" 6.
Maternal Pharmacokinetics
Pregnancy does not significantly alter propranolol disposition or clearance 10. However, pregnancy can alter drug effect—one study found greater heart rate reduction per unit concentration during pregnancy compared to postpartum, suggesting therapeutic ranges from non-pregnant patients may not apply 10.
Monitoring Protocol
Maternal Monitoring
- Serial echocardiography, particularly during second or third trimester when hemodynamic load is highest, or if clinical symptoms develop 2, 7
- Blood pressure and heart rate monitoring with dose adjustments as needed
- Electrolyte monitoring (normalize before surgery if planned) 6
Fetal Monitoring
- Fetal growth surveillance for IUGR
- Fetal bradycardia surveillance 2
- Fetal echocardiography may be considered for diagnosis of fetal conditions in context of prenatal counseling 2, 7
Neonatal Monitoring at Birth
- Bradycardia
- Hypoglycemia
- Hypotension
- Respiratory depression
Comparison with Other Beta-Blockers
Propranolol is preferred over atenolol, which is classified as FDA Category D and associated with significant fetal growth restriction, particularly when used earlier in gestational age and for longer duration 1. The 2003 ACC/AHA/ESC guidelines list atenolol as Class III (not recommended) for prophylactic therapy during pregnancy 5.
Propranolol and metoprolol are considered safe first-line agents with longer safety records 1. For LQTS specifically, nadolol or propranolol are preferred over metoprolol due to more breakthrough cardiac events with metoprolol and atenolol 6.
Breastfeeding
Propranolol is excreted in human milk, with maximum infant dose approximately 0.1% of maternal dose 11. The 2023 EASL guidelines indicate propranolol is compatible with breastfeeding 8. Beta-blocker therapy is considered safe while breastfeeding for LQTS patients 6. Caution should be exercised, but breastfeeding is not contraindicated 3.
Common Pitfalls to Avoid
- Do not switch from propranolol to metoprolol during pregnancy if already on propranolol for LQTS 6
- Do not use atenolol as first-line therapy due to higher fetal risk 1, 5
- Do not abruptly discontinue beta-blockers, particularly in LQTS patients where postpartum risk is elevated 4, 6
- Do not assume therapeutic ranges from non-pregnant patients apply during pregnancy 10
- Ensure neonatal monitoring facilities are available at delivery 3
Special Circumstances
Surgery: Continue beta-blockers perioperatively, normalize electrolytes, and avoid certain anesthetic agents (sevoflurane, succinylcholine) that prolong QT interval 6.
Delivery: Vaginal delivery is safe with adequate analgesia; minimize labor duration to avoid protracted adrenergic surges. Cesarean section should be reserved for obstetric or emergency maternal health reasons 2, 7.
Severe/Acute Arrhythmias: For hemodynamically unstable arrhythmias, electrical cardioversion is preferred and can be performed with minimal fetal risk 2, 4, 7.